Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9670.3273
Address
Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$2,170.00
1 week
0%
1 month
0%
YTD
-12.5%
1 year
-22.22%
All time high
0.62
EPS 3 yr Growth
-32.00%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-35.20%
ROIC
-68.70%
Interest Coverage
N/A
Quick Ratio
5.50
Shares on Issue (Fully Dilluted)
2056m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 August 24 |
PAT-DX1 GMP specification testing update
×
PAT-DX1 GMP specification testing update |
23 August 24 |
Appendix 4E and 2024 Annual Report
×
Appendix 4E and 2024 Annual Report |
23 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 July 24 |
Further update on PAT-DX1 GMP manufacturing run
×
Further update on PAT-DX1 GMP manufacturing run |
23 July 24 |
Appendix 4C - Quarterly - 30 June 2024
×
Appendix 4C - Quarterly - 30 June 2024 |
01 July 24 |
Update on GMP manufacturing run of PAT-DX1
×
Update on GMP manufacturing run of PAT-DX1 |
30 April 24 |
Appendix 4C - Quarterly - 31 March 2024
×
Appendix 4C - Quarterly - 31 March 2024 |
09 April 24 |
Positive preclinical data for deoxymabs in vasculitis
×
Positive preclinical data for deoxymabs in vasculitis |
22 March 24 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
22 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
04 March 24 |
Presentation to highlight broader potential of Deoxymabs
×
Presentation to highlight broader potential of Deoxymabs |
23 February 24 |
Appendix 4D - Half Year Accounts - 31 December 2023
×
Appendix 4D - Half Year Accounts - 31 December 2023 |
23 January 24 |
Appendix 4C - Quarterly - 31 December 2023
×
Appendix 4C - Quarterly - 31 December 2023 |
22 December 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
13 December 23 |
GMP Production of PAT-DX1 Next Quarter
×
GMP Production of PAT-DX1 Next Quarter |
29 November 23 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
29 November 23 |
Change of Director's Interest Notices x2
×
Change of Director's Interest Notices x2 |
15 November 23 |
Chair's Address and CEO Presentation to 2023 AGM
×
Chair's Address and CEO Presentation to 2023 AGM |
15 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
15 November 23 |
Amended Constitution
×
Amended Constitution |
13 November 23 |
Notification of Expiry of PABOA Listed Options
×
Notification of Expiry of PABOA Listed Options |
08 November 23 |
Patrys Receives R&D Tax Incentive Refund
×
Patrys Receives R&D Tax Incentive Refund |
20 October 23 |
Appendix 4C - Quarterly - 30 September 2023
×
Appendix 4C - Quarterly - 30 September 2023 |
19 October 23 |
Data to be presented at leading brain cancer conference
×
Data to be presented at leading brain cancer conference |
12 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.